Moleculin Biotech Faces Nasdaq Non-Compliance Notice

An announcement from Moleculin Biotech ( (MBRX) ) is now available.

On May 23, 2025, Moleculin Biotech received a notification from Nasdaq indicating non-compliance with the Listing Rule 5550(b)(1) due to insufficient stockholders’ equity. The company has 45 days to submit a compliance plan, and if accepted, may receive an extension to meet the requirements, though there is no guarantee of success if an appeal is needed.

The most recent analyst rating on (MBRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. operates in the biotechnology industry, focusing on the development of oncology drug candidates.

Average Trading Volume: 1,401,436

Technical Sentiment Signal: Sell

Current Market Cap: $13.28M

For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.